Item 1.01 Entry into a Material Definitive Agreement.

On September 28, 2021, Mirum Pharmaceuticals, Inc. (the "Company") entered into Amendment No. 1 to Revenue Interest Purchase Agreement (the "Amendment") with Mulholland SA LLC ("Purchaser Agent") and the purchasers (the "Purchasers") party to the Revenue Interest Purchase Agreement, dated as of December 8, 2020 (the "RIPA"), by and among the Company, Purchaser Agent and the Purchasers. The Amendment amends the RIPA to, among other things, permit the Company to transfer its Specified Priority Review Voucher (as defined therein).

As consideration for the Purchasers agreeing to permit the transfer of the Specified Priority Review Voucher, the Company has agreed to maintain the proceeds received by the Company in respect of the transfer in a segregated account, subject to the Purchaser Agent's control, and maintain the balances therein in cash or cash equivalents (the "Segregated Account"). Further, should the Company fail to comply with the agreements governing the Segregated Account and maintenance of the balances therein, an automatic put option event shall be deemed to have occurred under the RIPA.

All other material terms, including the rights of the Purchaser Agent following the occurrence of a put option event, and covenants in the RIPA remain unchanged.

The foregoing description of the material terms of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed herewith and incorporated herein by reference.

Item 8.01 Other Events.

On September 29, 2021, the Company announced that the U.S. Food and Drug Administration (the "FDA") completed its review of the Company's new drug application ("NDA") for LIVMARLI™ (maralixibat) oral solution, a minimally absorbed ileal bile acid transporter inhibitor, for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older, and approved the NDA. In connection with approval of the NDA, the FDA issued the Company a rare pediatric disease priority review voucher pursuant to Section 529 of the Federal Food, Drug, and Cosmetic Act. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit No.       Description

10.1                Amendment No. 1 to Revenue Interest Purchase Agreement, dated
                  September 28, 2021

99.1                Press Release, dated September 29, 2021

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses